Amgen to Buy Stake in Chinese Cancer-Drugmaker BeiGene

Date : 10/31/2019 @ 9:07PM
Source : Dow Jones News
Stock : Amgen Inc (AMGN)
Quote : 234.82  -1.93 (-0.82%) @ 7:38PM

Amgen to Buy Stake in Chinese Cancer-Drugmaker BeiGene

Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more Amgen Charts.
By Allison Prang 

U.S. pharmaceutical company Amgen Inc. said it is buying a roughly 20% stake in a Chinese biotechnology company focused on oncology for $2.7 billion in cash.

In taking the stake, Amgen said Beijing-based BeiGene Ltd. is going to commercialize certain Amgen treatments in China and will split those earnings or losses.

BeiGene is going to commercialize three different Amgen products: Xgeva, a prescription bone treatment; Kyprolis, a treatment for myeloma; and Blincyto, a leukemia treatment. BeiGene will ultimately get to keep one of those treatments, Amgen said.

BeiGene is also going to work with Amgen on 20 of Amgen's oncology medicines.

Amgen expects the deal to close early next year.

Write to Allison Prang at


(END) Dow Jones Newswires

October 31, 2019 16:52 ET (20:52 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.